Medlab Clinical Ltd (ASX:MDC) has received the first shipment of NanaBis
, the company's patented cannabis-based medicine, from Tasmanian Alkaloids Pty Ltd (TASALK).
In line with a commercial agreement executed in January, NanaBis production and analytical services have been transferred to TASALK.
This allows for manufacturing to be ramped up, increases overall product quality and supports a stronger manufacturing compliance for the Australian Therapeutic Goods Administration, US Food and Drug Administration and the European Medicines Agency.
"Continues to grow"[hhmc]
Medlab chief executive officer Dr Sean Hall said: “With the recent launch of the Observational Study and successful completion of the Phase 2 Advanced Cancer Pain Trial at Royal North Shore Hospital, demand for NanaBis continues to grow.
“Being able to partner with TASALK is very exciting and allows Medlab to increase production capacities drastically over the short-term and therefore to meet increased demand.”
Increased demand[hhmc]
The company reported that March quarterly revenue was achieved for NanaBis with aRead More – Source
[contf]
[contfnew]
Proactiveinvestors
[contfnewc]
[contfnewc]
